

# Takami Sato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8244453/publications.pdf>

Version: 2024-02-01

77  
papers

2,860  
citations

201385

27  
h-index

182168

51  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Uveal Melanoma Copy Number Subtypes Including an Ultra-High-Risk Group. <i>Ophthalmology Science</i> , 2022, 2, 100121.	1.0	4
2	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1939-1948.	0.8	29
3	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
4	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. <i>Oncogene</i> , 2021, 40, 618-632.	2.6	28
5	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 3190-3200.	3.2	35
6	Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 1104.	1.7	8
7	Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. <i>Current Protocols</i> , 2021, 1, e110.	1.3	3
8	Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells. <i>Cancer Research</i> , 2021, 81, 1137-1137.	0.4	6
9	Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. <i>Journal of Biological Chemistry</i> , 2021, 297, 101033.	1.6	12
10	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
11	The Role of HGF/MET Signaling in Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5457.	1.7	15
12	Genetic Landscape and Emerging Therapies in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5503.	1.7	17
13	Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5749.	1.7	10
14	IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 52-62.	1.5	37
15	An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. <i>Cancers</i> , 2020, 12, 117.	1.7	25
16	Unique Geospatial Accumulations of Uveal Melanoma. <i>American Journal of Ophthalmology</i> , 2020, 220, 102-109.	1.7	4
17	A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2020, 30, 574-579.	0.6	12
18	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1719-1726.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 405.	1.7	28
20	Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. <i>Journal of Translational Medicine</i> , 2020, 18, 208.	1.8	18
21	A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22059-e22059.	0.8	7
22	A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. <i>Radiology</i> , 2019, 293, 223-231.	3.6	42
23	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. , 2019, 7, 104.		43
24	Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	4
25	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. <i>Oncologist</i> , 2019, 24, e930-e942.	1.9	41
26	Effects of Oncogenic G $\hat{1}$ ±q and G $\hat{1}$ ±11 Inhibition by FR900359 in Uveal Melanoma. <i>Molecular Cancer Research</i> , 2019, 17, 963-973.	1.5	68
27	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	49
28	Effects of Oncogenic G $\hat{1}$ ± q and G $\hat{1}$ ± 11 Inhibition by FR900359 in Uveal Melanoma. <i>FASEB Journal</i> , 2019, 33, 815.9.	0.2	0
29	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9592-9592.	0.8	4
30	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
31	Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma. <i>Ophthalmology</i> , 2018, 125, 210-217.	2.5	53
32	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 516-528.	1.9	55
33	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 439-445.	1.2	10
34	Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1392-1400.	0.9	12
35	Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. <i>American Journal of Surgery</i> , 2017, 214, 884-890.	0.9	5
36	Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. <i>Journal of Translational Medicine</i> , 2017, 15, 145.	1.8	33

#	ARTICLE	IF	CITATIONS
37	PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy, 2017, 9, 1323-1330.	1.0	64
38	Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.. Journal of Clinical Oncology, 2017, 35, 9531-9531.	0.8	18
39	Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget, 2017, 8, 14428-14442.	0.8	27
40	Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. American Journal of Pathology, 2016, 186, 43-56.	1.9	20
41	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldenceI-T). Future Oncology, 2016, 12, 751-762.	1.1	18
42	Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.. Journal of Clinical Oncology, 2016, 34, 9541-9541.	0.8	7
43	Resolution of pre-cancerous and non-melanoma skin cancers after immune checkpoint inhibitor treatments.. Journal of Clinical Oncology, 2016, 34, e14540-e14540.	0.8	5
44	Thyroid-related laboratory abnormalities to predict treatment-limiting adverse events in melanoma patients treated with immune checkpoint blockade.. Journal of Clinical Oncology, 2016, 34, e14536-e14536.	0.8	1
45	Circulating cell free DNA to predict recurrence in uveal melanoma.. Journal of Clinical Oncology, 2016, 34, 9569-9569.	0.8	1
46	Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine, 2015, 2, 1821-1826.	2.7	38
47	Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2015, 26, 523-532.e2.	0.2	70
48	Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. American Journal of Roentgenology, 2015, 205, 429-433.	1.0	31
49	Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Research, 2015, 75, 2737-2748.	0.4	57
50	Potential survival benefit of adjuvant sunitinib in high risk uveal melanoma.. Journal of Clinical Oncology, 2015, 33, e20046-e20046.	0.8	1
51	Unique clustering of uveal melanoma in young females.. Journal of Clinical Oncology, 2015, 33, e20054-e20054.	0.8	0
52	Combination treatment with ipilimumab and immunoembolization in metastatic uveal melanoma: A feasibility study.. Journal of Clinical Oncology, 2015, 33, e20015-e20015.	0.8	0
53	Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell and Melanoma Research, 2014, 27, 297-308.	1.5	42
54	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359

#	ARTICLE	IF	CITATIONS
55	Tumor Necrosis Factor- $\alpha$ Blockade and Development of Uveal Melanoma: Expected Adverse Effect or Just Coincidence?. Mayo Clinic Proceedings, 2014, 89, 1467-1470.	1.4	0
56	Transhepatic Therapies for Metastatic Uveal Melanoma. Seminars in Interventional Radiology, 2013, 30, 039-048.	0.3	38
57	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	12
58	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	25
59	Development of renal cell carcinoma in patients with primary uveal melanoma.. Journal of Clinical Oncology, 2013, 31, e15563-e15563.	0.8	0
60	High-Dose Vincristine Sulfate Liposome Injection (Marqibo <sup>®</sup> ) Is Not Associated With Clinically Meaningful Hematologic Toxicity. Blood, 2013, 122, 2676-2676.	0.6	0
61	A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Research, 2012, 22, 440-446.	0.6	76
62	Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 145-155.	2.0	32
63	Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study.. Journal of Clinical Oncology, 2012, 30, 8560-8560.	0.8	0
64	Correlation of caveolin 1 expression with disease-free survival in skin melanoma.. Journal of Clinical Oncology, 2012, 30, e19016-e19016.	0.8	0
65	Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunologic Research, 2011, 51, 170-182.	1.3	215
66	Radioembolization as Salvage Therapy for Hepatic Metastasis of Uveal Melanoma: A Single-Institution Experience. American Journal of Roentgenology, 2011, 196, 468-473.	1.0	111
67	Locoregional Management of Hepatic Metastasis From Primary Uveal Melanoma. Seminars in Oncology, 2010, 37, 127-138.	0.8	84
68	The biology and management of uveal melanoma. Current Oncology Reports, 2008, 10, 431-438.	1.8	38
69	Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology, 2008, 26, 5436-5442.	0.8	83
70	Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Research, 2005, 15, 297-304.	0.6	116
71	Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 53-61.	2.0	13
72	Locoregional immuno(bio)therapy for liver metastases. Seminars in Oncology, 2002, 29, 160-167.	0.8	25

#	ARTICLE	IF	CITATIONS
73	Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases. , 2001, 94, 531.		4
74	Paclitaxel and tamoxifen. , 2000, 88, 79-87.		39
75	Protracted survival after resection of metastatic uveal melanoma. Cancer, 2000, 89, 1561-1568.	2.0	138
76	Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunology, Immunotherapy, 1996, 42, 263-267.	2.0	26
77	Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine. Cancer Immunology, Immunotherapy, 1996, 43, 174-179.	2.0	12